Abstract:Abstract Gene editing is now routine in all prokaryotic and metazoan cells but has not received much attention in immune cells when the CRISPR-Cas9 technology was introduced in the field of mammalian cell biology less than ten years ago. This versatile technology has been successfully adapted for gene modifications in human myeloid cells and T cells, among others, but applications to human primary B cells have been scarce and limited to activated B cells. This limitation has precluded conclusive studies into cell activation, differentiation or cell cycle control in this cell type. We report on highly efficient, simple and rapid genome engineering in primary resting human B cells using nucleofection of Cas9 ribonucleoprotein complexes. We provide proof-of-principle of gene editing in quiescent human B cells using two model genes: CD46 and CDKN2A . The latter encodes the cell cycle regulator p16 INK4a which is an important target of Epstein-Barr virus (EBV). Infection of B cells carrying a knockout of CDKN2A with wildtype and EBNA3 oncoprotein mutant strains of EBV allowed us to conclude that EBNA3C controls CDKN2A , the only barrier to B cell proliferation in EBV infected cells. Together, this approach enables efficient targeting of specific gene loci in quiescent human B cells supporting basic research as well as immunotherapeutic strategies. Author summary Human hematopoietic stem cells and their derivatives of the myeloid and lymphoid lineages are important targets for gene correction or modifications using the CRISPR-Cas9 technology. Among others, this approach can support site-specific insertion of chimeric antigen receptors (CARs) or T cell receptors (TCRs) into primary T cells. Their subsequent adoptive transfer to patient donors is a promising immunotherapeutic concept that may control chronic infection or certain types of cancer. Human B cells have a similar potential but, in contrast to T cells, they are very sensitive, difficult to handle, and short-lived ex vivo precluding their genetic modification. Here, we provide means to manipulate primary human B cells genetically using in vitro assembled Cas9 ribonucleoprotein complexes and electroporation for their delivery. Our study demonstrates near-to-complete loss of a model target gene and provides examples to evaluate a cellular gene with a critical role during infection with Epstein-Barr virus (EBV).

Facilitating Gene Editing in Human Lymphoma Cells Using Murine Ecotropic γ-Retroviruses

CRISPR/Cas9‐Mediated Genome Editing in Epstein‐Barr Virus‐Transformed Lymphoblastoid B‐Cell Lines

Highly efficient CRISPR-Cas9-mediated gene knockout in primary human B cells for functional genetic studies of Epstein-Barr virus infection

Efficient gene knockout in primary human and murine myeloid cells by non-viral delivery of CRISPR-Cas9

Rapid and Efficient Gene Editing for Direct Transplantation of Naive Murine Cas9+ T Cells

Author Correction: Generation of a CRISPR Activation Mouse That Enables Modelling of Aggressive Lymphoma and Interrogation of Venetoclax Resistance

In vivo human T cell engineering with enveloped delivery vehicles

Highly Efficient Homology-Driven Genome Editing in Human T Cells by Combining Zinc-Finger Nuclease Mrna and AAV6 Donor Delivery.

A Robust Protocol for CRISPR‐Cas9 Gene Editing in Human Suspension Cell Lines

Increasing Gene Editing Efficiency via CRISPR/Cas9- or Cas12a-Mediated Knock-In in Primary Human T Cells

Engineering single-cycle MeV vector for CRISPR-Cas9 gene editing

Viral and Non-Viral Systems to Deliver Gene Therapeutics to Clinical Targets

CRISPR/Cas9 Ribonucleoprotein (RNP) Complex Enables Higher Viability of Transfected Cells in Genome Editing of Acute Myeloid Cells

A novel CRISPR activation mouse enables modelling of aggressive lymphoma and interrogation of venetoclax resistance.

Peptide-mediated delivery of CRISPR enzymes for the efficient editing of primary human lymphocytes

Modulating Gene Expression in Epstein‐Barr Virus (ebv)‐positive B Cell Lines with CRISPRa and CRISPRi

Assessing gene function in human B cells: CRISPR/Cas9‐based gene editing and mRNA‐based gene expression in healthy and tumor cells

A Non-integrating Lentiviral Approach Overcomes Cas9-Induced Immune Rejection to Establish an Immunocompetent Metastatic Renal Cancer Model.

Increasing the Efficiency of CRISPR/Cas9-mediated Precise Genome Editing of HSV-1 Virus in Human Cells

Efficient Mutagenesis of Marek’s Disease Virus-Encoded microRNAs Using a CRISPR/Cas9-Based Gene Editing System

Biomaterials-mediated CRISPR/Cas9 delivery: recent challenges and opportunities in gene therapy